<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05022745</url>
  </required_header>
  <id_info>
    <org_study_id>ERAS for PLIA 2020-12</org_study_id>
    <nct_id>NCT05022745</nct_id>
  </id_info>
  <brief_title>ERAS Protocol for Single-level Posterior Lumbar Arthrodesisprospective Study.</brief_title>
  <official_title>ERAS Protocol for Single-level Posterior Lumbar Arthrodesis; a Randomized Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AZ Nikolaas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AZ Nikolaas</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Enhanced Recovery After Surgery (ERAS) is a multidisciplinary, multimodal approach aiming to&#xD;
      improve surgical outcomes. This study compares the length of hospital stay of patients&#xD;
      undergoing single-level posterior lumbar arthrodesis and treated with the ERAS protocol with&#xD;
      the hospital stay of patients treated according to the standard protocol.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hundred and ten patients scheduled for single-level posterior lumbar arthrodesis (PLIA) will&#xD;
      be randomized to be treated by the standard protocol or the Enhanced Recovery After Surgery&#xD;
      (ERAS) protocol. The ERAS protocol differs from the standard protocol in 4 phases:&#xD;
      pre-operative counseling and intake, day of surgery, the pre-operative patient preparation,&#xD;
      the per-operatively used analgesic and anesthetic drug combination, and the post-operative&#xD;
      care consisting of a more intensive physical therapy in the ERAS group. It is the objective&#xD;
      the mobilize patients more rapidly without compromising the comfort in terms of pain.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 8, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized controlled study in patients undergoing PLIA</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>The interventions described in the patient information brochure make masking impossible</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>2-3 days + 11 days</time_frame>
    <description>Number of days hospitalization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain intensity</measure>
    <time_frame>day of discharge</time_frame>
    <description>pain intensity on the day of discharge, measured on a 11-point numeric rating scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analgesic use, including opioids</measure>
    <time_frame>2-3</time_frame>
    <description>type and dose of analgesics used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>11-days readmission rate</measure>
    <time_frame>discharge + 11 days</time_frame>
    <description>patients who return to the hospital for reasons linked to the recovery after surgery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Mobility</condition>
  <condition>Opioid Use</condition>
  <condition>Instable Spine</condition>
  <arm_group>
    <arm_group_label>ERAS group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Posterior lumbar interbody fusion Multimodal, multidisciplinary patient care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Posterior lumbar interbody fusion Standard treatment pre-, per-, and post-operative</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Multimodal, multidisciplinary approach</intervention_name>
    <description>The patient management is adapted pre-operatively, per-operatively and post-operatively</description>
    <arm_group_label>ERAS group</arm_group_label>
    <arm_group_label>Standard group</arm_group_label>
    <other_name>standard treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Scheduled for a single level PLIA as treatment of mono segmental degenerative&#xD;
             instability, as seen on dynamic X-rays, after the failure of 6 months conservative&#xD;
             therapy Capable of understanding the provided information Giving informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Revision surgery Arthrodesis for trauma, neoplasms, infection, or listhesis due to&#xD;
             lysis. High dose opioid use (step 3 of the WHO pain ladder) Diabetes Cognitive&#xD;
             impairment (baseline dementia, cognitive dysfunction, or inability to consent to&#xD;
             participate).&#xD;
&#xD;
        Known kidney insufficiency: GFR &lt;30 mL/min/1.73 m2 Allergy/intolerance/contraindication to&#xD;
        any medication or component included in the ERAS pathway protocol Patients with a risk&#xD;
        factor for reflux&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Erik Van de Kelft, MD, PhD</last_name>
    <phone>+32 3 760 21 72</phone>
    <email>Erik.vandeKelft@aznikolaas.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Peter Verelst, MD</last_name>
    <phone>+32 3 760 85 48</phone>
    <email>Peter.Verelst@aznikolaas.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AZ Nikolaas</name>
      <address>
        <city>Sint-Niklaas</city>
        <zip>9100</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erik Van de Kelft, MD, PhD</last_name>
      <phone>+32 3 760 21 72</phone>
      <email>Erik.VandeKelft@aznikolaas.be</email>
    </contact>
    <contact_backup>
      <last_name>Peter Verelst, MD</last_name>
      <phone>+32 3 760 85 48</phone>
      <email>Peter.Verelst@aznikolaas.ve</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 20, 2021</study_first_submitted>
  <study_first_submitted_qc>August 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2021</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>AZ Nikolaas</investigator_affiliation>
    <investigator_full_name>Erik Van de Kelft, M.D., PhD</investigator_full_name>
    <investigator_title>Head of neurosurgery department</investigator_title>
  </responsible_party>
  <keyword>Enhanced recovery after surgery (ERAS)</keyword>
  <keyword>Posterior lumbar Interbody arthrodesis (PLIA)</keyword>
  <keyword>length of hospital stay (LOS)</keyword>
  <keyword>opioid use</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

